



CrandoOr™  
PRISTINE<sup>xv</sup>

---

Cranberry  
Extract.  
*Built from  
the source.*

---

**Urinary tract health and  
women's health formulations**




**FruitdOr**

## *A growing opportunity in women's health*

Urinary tract health remains one of the most relevant concerns in women's health today. Up to 60% of women will experience a UTI in their lifetime, with recurrence affecting up to half within a year.

This high-frequency need is driving demand for **daily, preventive solutions**, creating strong momentum for cranberry-based ingredients.



## *Built from the source*

*Cran d'Or™ Pristine XV was developed with a simple belief: quality starts at the source.*

By cultivating cranberries in dedicated Canadian fields, we select the most potent varieties and harvest them at peak maturity to help maximize PAC content. This upstream control ensures optimal raw material quality from the very beginning.

This integrated approach continues through processing and extraction, resulting in a cranberry extract that is consistent, traceable and fully mastered.

For brands, this means more than reliability. It offers the ability to tell a clear and compelling field-to-formula story, bringing transparency and authenticity to finished products.

## *A high-potency cranberry extract*

Cran d'Or™ Pristine XV is a standardized, high-potency cranberry extract designed for urinary tract health applications, particularly in women-focused formulations.

It delivers proanthocyanidins (PACs)—the key compounds studied in relation to urinary tract health—in a clean, concentrated format without excipients, making it easy to formulate across multiple delivery forms.

**15% STANDARDIZED PAC  
CONTENT (DMAC-A2)**


**36 MG PACS  
per 240 mg dose**

## Grounded in cranberry science

*Cranberry is one of the most extensively studied botanicals in urinary tract health.*

Research has shown that cranberry PACs, particularly type A, can help reduce the adhesion of certain bacteria such as E. coli to the urinary tract lining—an important factor in the development of infections.

Across the scientific literature, daily intake levels around 36 mg of PACs are frequently referenced in relation to urinary tract health, especially in women with recurrent concerns.



## Designed for performance and purity

*Cran d'Or™ Pristine XV combines efficacy-driven formulation with clean label expectations:*

◆ **15% standardized PAC content (DMAC-A2)**

◆ **36 mg PACs per 240 mg dose**

◆ **Powder format with good solubility**

◆ **No excipients or carriers**

◆ **Non-GMO Project Verified**

**Legal Notice:** These products are not intended to diagnose, treat, cure or prevent any disease. Please note that the physiological activity described herein is supported by the referenced studies reported. It is the responsibility of the distributors of finished products containing these ingredients to determine whether the claims made for these products are legal and in compliance with the laws of the country in which the products will be marketed.

### References

Wagenlehner F, et al. Social and economic burden of recurrent urinary tract infections and quality of life: a patient web-based study (GESPRIT). Expert Rev Pharmacoecon Outcomes Res 2018; 18:107-117.

Foxman B. Urinary tract infection syndromes: occurrence, recurrence, bacteriology, risk factors, and disease burden. Infect Dis Clin North Am 2014; 28:1-13.

Geerlings SE. Clinical presentations and epidemiology of urinary tract infections. Microbiol Spectr 2016; 4.

Gupta K, Trautner BW. Diagnosis and management of recurrent urinary tract infections in nonpregnant women. BMJ 2013; 346:f3140.

Anger J, et al. Recurrent uncomplicated urinary tract infections in women: AUA/CUA/SUFU guideline. 2019; 202:282-289.

Schappert SM, Rechtsteiner EA. Ambulatory medical care utilization estimates for 2007. Vital Health Stat 13. 2011; 169:1-38.

Jangid H, et al. Cranberry-derived bioactives for the prevention and treatment of urinary tract infections: antimicrobial mechanisms and global research trends in nutraceutical applications. Front Nutr 2025; 12:1502720.

Williams G, et al. Cranberries for preventing urinary tract infections. Cochrane Database Syst Rev 2023; 4:CD001321.

Xiong Z, et al. Preventive effect of cranberries with high dose of proanthocyanidins on urinary tract infections: a meta-analysis and systematic review. Front Nutr 2024; 11: 1422121.

Anger JT, et al. Updates to recurrent uncomplicated urinary tract infections in women: AUA/CUA/SUFU guideline. J Urol 2022; 208:536-541.



*We pamper our berries every step of the way. Learn more about our sustainability practices.*



## *Versatile across applications*



CAPSULES



TABLETS



GUMMIES



STICK PACKS



SOFTGELS

## *Why choose Cran d'Or™ Pristine XV?*

- Built from the source with vertical integration
- Standardized PAC content aligned with scientific literature
- Clean, excipient-free extraction
- Designed for urinary tract health applications
- Enables transparency, consistency and brand storytelling

# FruitdOr

nutra.fruitdor.ca  
info@fruitdor.com | 819 385-1126